- Eli Lilly’s experimental drug lowers risk of heart disease by 94%: study New York Post
- Eli Lilly’s Heart Drug Lepodisiran Cuts Lipoprotein Lp(a) for Year in Study Bloomberg
- Trial Shows a Single Dose of an Experimental Therapy Reduces Lipoprotein(a), an Important Heart Disease Risk Factor, More than 94% for Nearly a Year Cleveland Clinic Newsroom
- Sustained Reductions in Lp(a) Achieved With Novel siRNA Drug Medscape
- One dose of experimental therapy reduced lipoprotein(a) more than 94% for nearly a year American Heart Association
- View Full Coverage on Google News
Tag Archives: drug
Weight Loss Drug Wegovy Can Cut Heart Attack Risk for Some, Study Shows – The New York Times
- Weight Loss Drug Wegovy Can Cut Heart Attack Risk for Some, Study Shows The New York Times
- Novo Nordisk: Wegovy heart benefits due to more than weight loss Reuters
- Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else? CNN
- Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds The Associated Press
- Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine Yahoo Finance
- View Full Coverage on Google News
Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds – KSL.com
- Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds KSL.com
- Novo Nordisk: Wegovy heart benefits due to more than weight loss Reuters
- Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else? CNN
- Weight Loss Drug Wegovy Can Cut Heart Attack Risk for Some, Study Shows The New York Times
- Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine Yahoo Finance
- View Full Coverage on Google News
Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end – CNBC
- Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end CNBC
- Bond yield rally has already priced in another potential rate hike, says Parametric’s Nisha Patel CNBC Television
- Earnings playbook: Your guide to trading another busy week of reports, including Apple and Pfizer CNBC
- Interest rates are ‘hollowing out’ the underlying market structure, says 3Fourteen’s Warren Pies CNBC Television
- Analyzing the market sell-off: Routine S&P 500 correction or something more serious? CNBC
- View Full Coverage on Google News
Biogen’s Alzheimer’s drug slows cognitive decline in early study – STAT
- Biogen’s Alzheimer’s drug slows cognitive decline in early study STAT
- More convenient form of breakthrough Alzheimer’s drug Leqembi shows promising results in study CNBC
- New studies find benefits in very early drug treatment of Alzheimer’s Financial Times
- New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease | Biogen Biogen
- Alzheimer’s drug Leqembi could be given as shots rather than IV infusion, study suggests CNN
- View Full Coverage on Google News
‘Parasite’ Star Lee Sun-kyun Removed From Project Amid Police Probe Over Suspected Drug Use – Hollywood Reporter
- ‘Parasite’ Star Lee Sun-kyun Removed From Project Amid Police Probe Over Suspected Drug Use Hollywood Reporter
- ‘Parasite’ actor Lee Sun-kyun booked by police over suspected drug use NME
- “I See Handcuffs” — Eerie Video Of Fortune Teller Predicting Lee Sun Kyun’s Future Goes Viral Amidst His Drug Allegations Koreaboo
- Gangnam Entertainment Venue Manager claims Lee Sun Gyun was a VIP guest indulging in drug use allkpop
- Lee Sun-kyun drops out of K-drama ‘No Way Out’ amid drug investigation controversy NME
- View Full Coverage on Google News
Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial – Endpoints News
- Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial Endpoints News
- Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Yahoo Finance
- Sanofi reaps rewards of immunology investment with eczema results MarketWatch
- ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress GlobeNewswire
- Amlitelimab A Revolutionary Solution for Atopic Dermatitis Best Stocks
- View Full Coverage on Google News
Alnylam gets surprise FDA rejection for rare disease drug – Boston Business Journal – The Business Journals
- Alnylam gets surprise FDA rejection for rare disease drug – Boston Business Journal The Business Journals
- Alnylam abandons Onpattro expansion in US as FDA spurns rare heart disease bid FiercePharma
- FDA rejects Alnylam’s request to expand approval of one of its drugs to include heart patients The Boston Globe
- Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval Yahoo News
- Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Business Wire
Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder | National Institute on Drug Abuse – National Institute on Drug Abuse
- Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder | National Institute on Drug Abuse National Institute on Drug Abuse
- Larger dose of existing medication eyed as response to fentanyl Washington Examiner
- What you need to know about a new type of synthetic opioids The Morning Call
- New study suggests higher buprenorphine doses could help save lives News-Medical.Net
- Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder National Institutes of Health (.gov)
- View Full Coverage on Google News
UFC’s Mayra Bueno Silva calls for change after failed drug test due to ADHD medication – MMA Junkie
- UFC’s Mayra Bueno Silva calls for change after failed drug test due to ADHD medication MMA Junkie
- Mayra Bueno Silva Opens Up On Positive Drug Test, Responds To Julianna Pena | MMA Fighting MMAFightingonSBN
- Mayra Bueno Silva vows to “smash” Julianna Pena following her comments after failed drug test | BJPenn.com BJPENN.COM
- Mayra Bueno Silva Calls for Change After Failed Drug Test Due to ADHD Medication MMA Junkie
- Mayra Bueno Silva responds to ‘easy money’ Julianna Pena: ‘I will smash her for five rounds. I promise’ MMA Mania
- View Full Coverage on Google News